Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for…
Ross Camidge, MD, PhD of University of Colorado Cancer Center @CUCancerCenter Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for…
Ross Camidge, MD, PhD on Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious…
Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly…
Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly…
Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly…
Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey…
Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey…
Robert Epstein, MD, MS of Epstein Health LLC on real-world burden of chemotherapy-induced myelosuppression: results of a U.S. online survey…
Amar Gajjar, MD of St. Jude Children’s Research Hospital @StJudeResearch discusses genomics paving the way to better infant medulloblastoma therapy…
Amar Gajjar, MD of St. Jude Children’s Research Hospital @StJudeResearch discusses genomics paving the way to better infant medulloblastoma therapy…
J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health…
J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health…
J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health…
Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic…
Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic…
Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic…
Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer…
Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer…
Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer…
Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder…
Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder…
George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving…
George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving…
George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving…
George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving…
George Peoples, MD of Heat Biologics @HeatBiologics discusses tumor antigen expression and survival of patients with previously-treated advanced NSCLC receiving…
Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results.…
Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results.…
Earn CME: https://www.naccme.com/program/20-hemcovid-4 In this webcast, Drs. Joseph R. Mikhael leads a roundtable discussion with Drs. Jessica K. Altman, Michael…
Earn CME: https://www.naccme.com/program/20-hemcovid-3 In this webcast, Drs. Joseph R. Mikhael and Nina Shah discuss challenges faced by US healthcare practitioners…
Earn CME: https://www.naccme.com/program/20-hemcovid-2 In this webcast, Drs. Joseph R. Mikhael and John P. Leonard discuss challenges faced by US healthcare…
Earn CME: https://www.naccme.com/program/20-hemcovid-1 In this webcast, Drs. Joseph R. Mikhael, John P. Leonard, Nina Shan, and Michael J. Satlin discuss…
Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results.…
Kent Nastiuk, MD of Roswell Park @RoswellPark discusses prostate tumor-derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. Read here: https://insight.jci.org/articles/view/127018?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research
Kent Nastiuk, MD of Roswell Park @RoswellPark discusses prostate tumor-derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. Read here: https://insight.jci.org/articles/view/127018?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research
Philadelphia, PA (June 8, 2020) –  Oncoceutics announced today a Brown University award of $3.4 million that will be used…
Jesus Berdeja, MD of Sarah Cannon Research Institute discusses the BCMA CAR-T therapy JNJ-4528 in pretreated patients with multiple myeloma.…
Jesus Berdeja, MD of Sarah Cannon Research Institute discusses the CAR-T therapy JNJ-4528 in pretreated patients with multiple myeloma. Read…
Nicholas Vogelzang, MD of Comprehensive Cancer Center @CCCNevada discusses the single arm, phase 2, TRITON2 clinical trial supported FDA approval…
Mikkael Sekeres, MD @MikkaelSekeres of Cleveland Clinic @ClevelandClinic discusses the phase II study of pevonedistat + azacitidine vs. A in…
Mikkael Sekeres, MD @MikkaelSekeres of Cleveland Clinic @ClevelandClinic discusses the phase II study of pevonedistat + azacitidine vs. A in…
Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year’s virtual ASCO the phase I open label dose…
Jame Abraham, MD @jamecancerdoc of Cleveland Clinic @ClevelandClinic discusses at this year’s virtual ASCO the phase I open label dose…
Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed…
Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed…
Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85% of newly…
Elise De, MD of Massachussetts General Hospital @MassGeneralNews discusses the robotic assisted urethral diverticulectomy.
Elise De, MD of Massachussetts General Hospital @MassGeneralNews discusses the robotic assisted urethral diverticulectomy.
Salma Jabbour, MD @SalmaJabbour1 of Rutgers Cancer Institute of New Jersey @RutgersCancer discusses phase 2 Study of pembro plus platinum…
Salma Jabbour, MD @SalmaJabbour1 of Rutgers Cancer Institute of New Jersey @RutgersCancer discusses how patients tolerated this therapy? – Phase…
Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL:…
Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL:…
Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL:…
Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium…
Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium…
John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin…
John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin…
John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin…
Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural…
Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural…
Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural…
Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally…
Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally…
Philadelphia, PA (May 28, 2020) – Oncoceutics, Inc. announced that it and its collaborators will present several abstracts at the…
Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC…
Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC…
Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC…
Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC…
Fumito Ito, MD, PhD of Roswell Park @RoswellPark discusses CX3CR1–CD8+ T cells are critical in antitumor efficacy but functionally suppressed…
Tannishtha Reya, PhD of UCSD @UCSDHealth discusses using genome-wide CRISPR technology to find leukemia’s vulnerabilities. … A team of researchers…
Tannishtha Reya, PhD of UCSD @UCSDHealth discusses using genome-wide CRISPR technology to find leukemia’s vulnerabilities. _____________ A team of researchers…
Heather Losey, PhD of Alkermes discusses ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile…
Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1…
Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1…
Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1…
Philadelphia, PA (May 19, 2020) – Oncoceutics, Inc. announced that the latest research findings with ONC201 and its novel class…
Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer.…
Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer.…
Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer.…
Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell…
Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell…
Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell…
Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with…
Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with…
Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to…
Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to…
Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to…
Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast…
Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast…
Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast…
Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast…
Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast…
Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast…
David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of…
Eyal Lebel, MD of Princess Margaret Cancer Centre @pmcancercentre discusses the rare recurrence of cutaneous anaplastic large cell lymphoma. Read…
Sai-Hong Ignatius Ou, MD PhD Health Science Clinical ProfessorChao Family Comprehensive Cancer Center University of California Irvine School of Medicine…
David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of…
David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of…
Richard Penson, MD of Massachusetts General Hospital @MassGeneralNews discusses a randomized phase III of olaparib versus nonplatinum chemotherapy in patients…
Richard Penson, MD of Massachusetts General Hospital @MassGeneralNews discusses a randomized phase III of olaparib versus nonplatinum chemotherapy in patients…
Adilia Hormigo, MD of Mount Sinai Health System @MountSinaiNYC discusses the clinical study of the safety and tolerability of laser…
Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization…
Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization…
Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization…
Yuman Fong, MD surgical oncologist at City of Hope @cityofhope discusses the phase 1a/1b, open-label first-in-human study of the safety, tolerability, and…
Yuman Fong, MD surgical oncologist at City of Hope @cityofhope discusses the phase 1a/1b, open-label first-in-human study of the safety, tolerability, and…
Udai Banerji, MD @udai_banerji of The Institute of Cancer Research and Jonathan Pachter, PhD of Verastem Oncology discuss the new…
Philadelphia, PA (May 5, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates Brain Tumor Awareness Month this…
Eyal Lebel, MD of Princess Margaret Cancer Centre @pmcancercentre discusses the rare recurrence of cutaneous anaplastic large cell lymphoma. Read…
Udai Banerji, MD @udai_banerji of The Institute of Cancer Research discusses the phase 1 study of the combination of a…
Udai Banerji, MD @udai_banerji of The Institute of Cancer Research discusses the phase 1 study of the combination of a…
Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with…
Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with…
Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with…
Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual…
Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual…
Ecaterina Dumbrava, MD of MD Anderson Cancer Center @MDAndersonNews discusses the phase I trial of COM701 presented at the virtual…
Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the importance of real…
Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the real world outcomes…
Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the real world outcomes…
Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer and…
Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC discusses if switch maintenance immunotherapy is a standard base treatment…
Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. How…
Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC answers what is the role of a switch maintenance immune…
Andrea Wang-Gillam, MD, PhD of Washington University School of Medicine @WUSTLmed answers if the phase I study of defactinib combined…
Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. Read…
Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC discusses switch maintenance immunotherapy, significantly slows the worsening of a…
Andrea Wang-Gillam, MD, PhD of Washington University School of Medicine @WUSTLmed discusses the phase I study of defactinib combined with…
Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes…
Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses the impact of multigenomic assays in premenopausal patients and those with…
Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes…
Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses using multigenomic assays in premenopausal patients and those with node-positive breast…
Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses using multigenomic assays in premenopausal patients and those with node-positive breast…
Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes…
Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in…
Laurie Schenkel of Ribon Therapeutics @RibonTx discusses a potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory…
Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways:…
Laurie Schenkel of Ribon Therapeutics @RibonTx discusses a potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory…
Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in…
Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways.…
Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in…
Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways.…
Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine explains how important it is to tailor treatment for triple-negative breast cancer patients.…
Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine answers how come interferon gamma is acting differently? _____________ Immunotherapies have revolutionized care…
Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine discusses tailoring revolutionary treatment for triple-negative breast cancer. _____________ Immunotherapies have revolutionized care…
Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews explains immunosuppression in tumors overall in the study. ______________ An active immune…
Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews answers what the effects are in activation for identifying molecular pathways that…
Paulo Rodriguez, PhD of Moffitt Cancer Center @MoffittNews discusses identifying molecular pathways that control immunosuppression in tumors. ______________ An active…
In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and…
In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and…
In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and…
In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and…
In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a…
In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a…
In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a…
In this video from our Cancer Basics series, Narjust Duma, MD, Assistant Professor and Thoracic Oncologist with the University of…
Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center discusses COVID 19 and…
Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center discusses COVID 19 and…
In partnership with Clinical Care Options, GRACE President Jack West, MD provides information regarding immunotherapy for advanced NSCLC, and discussing…
Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Julia Maues, breast…
Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Juanita Segura, lung…
Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Juanita Segura, lung…
Narjust Duma, MD, Assistant Professor and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center interviews Juanita Segura, lung…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.Dr.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.Jonathan…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.Jonathan…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.…
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.…
Terapias para el Cancer: Conocimientos Basicos (Cancer Therapy – Basics) ¿Que es oncologia geriátrica? What is Geriatric Oncology? Narjust (N.J.)…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Gail J.…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Ajay Chari…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Steven E.…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Gail J.…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Aaron C.…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Prashant Kapoor…
Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic…
Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic…
Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic…
Earn CME: https://www.naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment…
Earn CME: https://www.naccme.com/program/19-gdu… In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment…
Earn CME: https://naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment…
Earn CME: https://naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment…
Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for…
Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for…
Earn CME: https://www.naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse…
Earn CME: https://www.naccme.com/program/19-cpc-101-7 This webcast features a presentation by Dr. Gary H. Lyman that examines the potential benefits of incorporating…
Earn CME: https://www.naccme.com/program/19-cpc-101-6 This webcast features a presentation by Dr. Alexander B. Olawaiye that discusses the integration of PARP inhibitors…
Earn CME: https://www.naccme.com/program/19-cpc-101-5 This webcast features a presentation by Dr. Atish D. Choudhury that examines the latest clinical safety and…
Earn CME: https://www.naccme.com/program/19-cpc-101-4 This webcast features a presentation by Dr. Amir T. Fathi on best practices for the integration of…
Earn CME: https://www.naccme.com/program/19-cpc-101-3 This webcast features a presentation by Dr. David Jackman discusses the latest efficacy and safety data, indications,…
Earn CME: https://www.naccme.com/program/19-cpc-101-2 This webcast features a presentation by Dr. Gabriella Hobbs that examines the most recent evidence-based guidelines to…
Earn CME: https://www.naccme.com/program/19-cpc-101-1 This webcast features a presentation by Dr. Nicole M. Kuderer that examines pharmacological profiles of novel and…
Earn CME: https://www.naccme.com/program/19-lm-15 In this webcast from the ‘New and Emerging Agents in MCL’ symposium during the 2019 Lymphoma &…
Earn CME: https://www.naccme.com/program/19-lm-14 In this webcast from the ‘Revolutionizing the R/R DLBCL Treatment Paradigm: Innovative, Strategic & Targeted Approaches’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K…
Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K…
Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K…
Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the…
Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the…
Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the…
Earn CME: https://www.naccme.com/program/19-lm-09 In this webcast from the ‘Understanding Waldenström’s Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and…
Earn CME: https://www.naccme.com/program/19-lm-09 In this webcast from the ‘Understanding Waldenström’s Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and…
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’…
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’…
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’…
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’…
Earn CME: https://www.naccme.com/program/19-lm-03 In this webcast from the ‘Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges’ symposium during…
Earn CME: https://www.naccme.com/program/19-lm-03 In this webcast from the ‘Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges’ symposium during…
Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Earn CME: https://www.naccme.com/program/19-lm-04 In this webcast from the ‘Recent Advances in Acute Leukemia Management’ symposium during the 2019 Lymphoma &…
Earn CME: https://www.naccme.com/program/19-lm-05 In this webcast from the ‘Multiple Myeloma: Treatment Challenges and Updates’ symposium during the 2019 Lymphoma &…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the alkylating properties in the treatment of relapsed/refractory multple myeloma. ________________ Oncopeptides highlighted…
Zachary Frosch, MD of Penn Medicine @PennMedicine explains that more prospective data is needed to validate stratification of molecular risk…
Zachary Frosch, MD of Penn Medicine @PennMedicine answers how stratification of molecular risk in aggressive b-cell lymphoma is validated. Diffuse…
Zachary Frosch, MD of Penn Medicine @PennMedicine discusses stratification of molecular risk in aggressive b-cell lymphoma. Diffuse large B-cell lymphoma…
According to GlobalData, a leading data and analytics firm, India-based Curadev’s March 2020 licensing agreement with Bayer for the discovery…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the next steps for the ongoing trial once they receive FDA approval and…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides answers where does melphalan flufenamide fit in the mix of RRMM treatment if broad-spectrum…
OneOncology, the national association of independent group oncologists, said today that enrolling patients at their affiliate practices in clinical trials…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses results of the HORIZON phase 2 data in RRMM. ________________ Oncopeptides highlighted its…